BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35863013)

  • 1. Conventional papillary thyroid carcinoma with intraglandular lymphatic dissemination shows more aggressive features.
    Lei Y; Feng S; Yu Q; Shen G; Yuan L; Huang W
    Jpn J Clin Oncol; 2022 Nov; 52(11):1311-1320. PubMed ID: 35863013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer.
    Giani C; Torregrossa L; Ramone T; Romei C; Matrone A; Molinaro E; Agate L; Materazzi G; Piaggi P; Ugolini C; Basolo F; Ciampi R; Elisei R
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4072-e4083. PubMed ID: 34231847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
    Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
    Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological Evidence of Lymph Node Metastasis in Papillary Thyroid Carcinoma.
    Can N; Tastekin E; Ozyilmaz F; Sezer YA; Guldiken S; Sut N; Sarikas N; Oz Puyan F; Guler B; Ayturk S; Celik M
    Endocr Pathol; 2015 Sep; 26(3):218-28. PubMed ID: 26209182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
    Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY
    Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and Prognostic Factors for BRAF
    Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
    Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
    Ito Y; Yoshida H; Maruo R; Morita S; Takano T; Hirokawa M; Yabuta T; Fukushima M; Inoue H; Tomoda C; Kihara M; Uruno T; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
    Endocr J; 2009; 56(1):89-97. PubMed ID: 18840924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.